If a patient is diagnosed with hairy cell leukemia but BRAF mutation analysis is negative, what does this indicate?

BRAF-Negative Hairy Cell Leukemia: Diagnostic Implications

A negative BRAF V600E mutation in a patient diagnosed with hairy cell leukemia indicates either hairy cell leukemia variant (HCLv), an aggressive IGHV4-34-expressing variant, or the rare presence of atypical BRAF mutations—all of which represent poor-risk features requiring careful diagnostic confirmation and consideration of alternative treatment approaches.

Diagnostic Significance

The absence of BRAF V600E mutation is a critical diagnostic and prognostic marker that fundamentally changes the clinical approach. The 2017 consensus guidelines explicitly identify absence of BRAFV600E mutation as a poor-risk feature that warrants special attention 1.

What BRAF-Negativity Suggests:

Hairy Cell Leukemia Variant (HCLv):

• Most likely diagnosis when BRAF V600E is absent
• Represents a distinct WHO-classified entity separate from classic HCL 1
• Characterized by more aggressive clinical behavior 2
• Typically presents with:
  • Leukocytosis (77% of cases) rather than leukopenia
  • Lymphocytosis (82% of cases)
  • Absence of monocytopenia (unlike classic HCL)
  • Splenomegaly (90% of cases)
• Immunophenotype differs: negative for CD25 and annexin A1 2, 3
• Associated with TP53 deletions (42%) and ATM deletions (22%) 2

IGHV4-34-Expressing Variant:

• Molecularly defined aggressive variant
• Lacks BRAF V600E mutation
• Can have phenotype of either HCL or HCLv 3
• More aggressive clinical course

Rare Atypical BRAF Mutations:

• Approximately 2% of cases may have non-V600E BRAF mutations (e.g., F595L, W604L) 4
• Some patients may have silent BRAF mutations
• Requires sequencing if ddPCR is negative 4

Clinical Implications

Treatment Considerations:

Standard purine analog therapy (cladribine/pentostatin) is less effective in BRAF-negative disease 3. The guidelines specifically recommend:

• Confirm diagnostic accuracy before proceeding with treatment 1
• Review immunophenotypic profile carefully (look for absence of CD25, annexin A1)
• Consider that these patients may have shorter remissions (<24 months) 1
• BRAF inhibitors (vemurafenib, dabrafenib) are not appropriate for BRAF-negative patients 5

Prognostic Impact:

BRAF-negative status indicates:

• More aggressive disease course
• Potentially shorter response duration to standard therapy
• Higher likelihood of requiring alternative therapeutic approaches
• Possible need for investigational agents 1

Recommended Next Steps:

1. Verify the diagnosis:

   • Repeat BRAF testing with sequencing (not just V600E-specific assays) 4
   • Confirm immunophenotype: check CD25, annexin A1, TRAP expression
   • Review peripheral blood for monocytopenia (present in classic HCL, absent in HCLv)
   • Assess for leukocytosis vs. leukopenia

2. Assess for poor-risk features:

   • Severe anemia
   • Spleen >10 cm below left costal margin
   • Cytogenetic abnormalities (17p/TP53, 11q/ATM deletions)

3. Treatment planning:

   • Consider enrollment in clinical trials for investigational agents 1
   • Options include: ibrutinib, moxetumomab pasudotox (immunotoxin targeting CD22)
   • Rituximab monotherapy or combination approaches may be considered
   • Avoid BRAF inhibitors in confirmed BRAF-negative disease

Critical Pitfall:

Do not assume all "hairy cell leukemia" responds identically to purine analogs. BRAF-negative disease represents biologically distinct entities that require different therapeutic strategies and have different expected outcomes. The absence of BRAF V600E should trigger immediate diagnostic review and consideration of alternative treatment pathways rather than proceeding with standard cladribine/pentostatin monotherapy.